Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.

CAR-T therapy can be effective in the management of refractory rheumatic diseases.

The principles of CAR-T therapy are founded on precise and specific actions against disease-related targets.

Further clinical trials are needed to validate the efficacy and safety of CAR-T therapy.

Introduction

Chimeric antigen receptor T cell (CAR-T) therapies have gained recognition as potentially curative treatments in patients with end-stage haematological cancers. An adoptive cell immunotherapy approach utilizes viral transduction or gene editing to modify T lymphocytes and engineer synthetic receptors on their surface. These receptors, known as CARs, possess an extracellular domain that can specifically bind to antigens, and a variable intracellular co-stimulatory domain that can trigger in vivo CAR-T expansion and persistence, leading to effective elimination of target tumour cells. CAR-T associated toxicities such as cytokine release syndrome (CRS), neurotoxicity [ 1 ] and prolonged B cell aplasia are well recognized. Treatment efficacy and refinement of CAR constructs has enabled safe delivery across patients with a wide breadth of diagnoses. Exploration of CAR-Ts in solid tumours, autoimmune and degenerative diseases and in earlier treatment pathways is underway. The successful application of CD19-targeted CAR T cells in refractory cases of autoimmune rheumatic diseases, including SLE, SSc and anti-synthetase syndrome (ASyS), offers a promising innovative treatment modality. In comparison with existing B cell depletion therapies, targeting CD19 has demonstrated a more rapid and profound therapeutic effect, enabling drug-free remission with manageable adverse events reported.

CAR-T therapy and its approval in cancer

CAR T cells were first constructed by Eshhar and colleagues in 1989 ( Fig. 1 ), aiming at expressing functional chimeric T cell receptors (TCR) that recognize antigens in a non-major histocompatibility complex (MHC)-restricted manner [ 2 ]. The first generation of CARs consisted of a single-chain variable fragment (scFv) derived from an antibody as the extracellular antigen-binding domain, a hinge or spacer, a transmembrane domain, and an intracellular signalling domain, CD3ζ, from a TCR–CD3 complex [ 3 ] ( Fig. 2 ). To increase the proliferative capacity, persistence and cytokine-secreting function of CAR T cells, the second generation included an intracellular co-stimulatory domain, e.g. CD28 or 4-1BB. CAR-edited T cells can specifically recognize and bind to targeted tumour cells. Activated intracellular domains further strengthen the immune response and targeting of tumour cells.

Efficacy, tolerance and safety of CAR-T therapy

The efficacy and tolerance of CAR T cells was proven in early phase clinical trials, and they were approved for clinical use in 2017 ( Fig. 1 ) [ 4 , 5 ]. By July 2023, six CAR-T products were licensed by the European Medicines Agency and the US Food and Drug Administration (FDA). These include CD19-targeting CAR T cells for relapsed refractory large B cell lymphoma (LBCL), follicular lymphoma, mantle cell lymphoma (MCL) and acute lymphoblastic leukaemia (ALL), and B cell maturation antigen (BCMA)-targeting products for relapsed refractory multiple myeloma [ 6 , 7 ]. Currently approved therapies use autologous T cells, which are collected through leukapheresis. The manufacturing process is complex and takes ∼3–4 weeks. T cells are first edited to express CARs through virus transduction. Synthetic CAR T cells are then expanded in vitro and cryopreserved for transport and storage. Prior to CAR-T infusion, patients undergo preparative lymphodepleting chemotherapy [ 8 ]. Early CAR-T-related toxicities including CRS and immune effector cell associated neurotoxicity syndrome (ICANS) are product and disease dependent and typically occur within 30 days of infusion, during which period patients are carefully monitored [ 1 , 4 , 5 ]. Tumour-lysis syndrome, neutropenic fevers and other chemotherapy-related toxicities may also occur along with CAR-T specific late toxicities such as prolonged cytopenia, B cell aplasia, hypogammaglobulinaemia, and in rare cases, delayed CRS/ICANS [ 4 , 5 ].

CRS is a multisystem inflammatory response to CAR T cell activation and expansion that can mimic sepsis. This cytokine storm typically results in fevers with or without hypoxia and/or hypotension, sometimes requiring critical care intervention. In rare cases, haemolymphophagocytic/macrophage activation syndrome can develop. The pathophysiology of ICANS is less well understood. Symptoms can range from mild tremor, poor concentration and lethargy to expressive aphasia, confusion and drowsiness. Patients may develop stroke-like symptoms, seizures and occasionally cerebral oedema. Baseline observations as well as neurological assessments are performed multiple times throughout a 24-h period. The latter includes an extended mini-mental state assessment, the Immune-effector Cell Encephalopathy (ICE) score, which evaluates the patients’ orientation, handwriting, and ability to follow commands, name items and count. Published consensus guidelines by the American Society for Transplantation and Cellular Therapy are followed to grade these toxicities [ 1 ] ( Table 1 ). Treatment algorithms endorsed by the European Society for Blood and Bone Marrow Transplantation [ 9 ], the European Haematology Association [ 8 ] and the American Society of Clinical Oncology [ 10 ] include supportive care with fluid replacement, oxygen supplementation and vasopressors as indicated, treatment of potentially underlying infections, as well as targeted therapies such as use of tocilizimab for CRS. Steroids can be effective for both CRS and ICANS, and in refractory or severe cases are combined with other immune modulators, e.g. anakinra (IL-1 receptor antagonist) and siltuximab (monoclonal anti-IL-6).

The largest UK experience to date is with axicabtagene (Yescarta ® ) and tisagenlecleucel (Kymriah ® ), fast-tracked and commissioned by NHS England for relapsed refractory LBCL [ 11 ] and paediatric ALL in 2019, and brexucabtagene (Tecartus ® ) for MCL in 2021 and adult ALL in 2023. The overall incidence of CRS reported is up to 95% across all grades for all products and indications, with grades 3–4 occurring in 5–13% of patients treated with axicabtagene or tisagenlecleucel for LBCL [ 12–16 ], 15% treated with brexucabtagene for MCL [ 17 , 18 ], and 30% treated with brexucabtagene for ALL [ 19 ]. The median time to onset was 2–4 days post-infusion (range 1–15) and the median duration 6–10 days (range 1–43). The incidence of all grade ICANS is 30% for tisagenlecleucel of which up to 10% are grades 3–4, and 60–80% for the other products with 30–40% attributed to grades 3–4. Severity of both CRS and ICANS is believed to be related to disease bulk, but most patients experience a full recovery with a treatment-related mortality in this patient population of <5% [ 4 ].

Clinical reports of CD19-targeted CAR-T therapy in autoimmune rheumatic diseases

The successful application of CAR-T therapy in haematological malignancies has inspired its use in refractory autoimmune rheumatic diseases (ARDs) [ 20 ]. Preclinical data suggested compelling evidence that CD19-targeted CAR CD8 + T cells possess the capability to effectively deplete CD19 + B cells, leading to the elimination of autoantibody production and subsequent reversal of lupus manifestations in both NZB/W F 1 and MRL/lpr mice models [ 21 ]. Additional clinical evidence has been reported as outlined in Table 2 .

Mougiakakos et al . first reported the use of autologous CD19-targeted CAR T cells in a 20-year-old female with refractory SLE [ 22 ]. The patient had active lupus nephritis, pericarditis, endocarditis, pleurisy, rash and arthritis, and failed treatment with high-dose glucocorticoids and multiple immunsuppressants previously, including two B cell-targeting biologics, rituximab and belimumab. After treatment with fludarabine (25 mg/m 2 /d intravenously [i.v.] from day −5 to day −3) and cyclophosphamide (1000 mg/m 2 /d i.v. on day −3), the patient received CAR T cells at a dose of 1.1 × 10 6 cells/kg body weight once, and experienced a rapid remission within 44 days, not only serologically with anti-double-strand DNA (dsDNA) antibodies turned negative and low completement C3 and C4 levels normalized, but also clinically with urine protein from above 2000 mg/g to <250 mg/g and SLEDAI-SELENA score from 16 to 0. No adverse events were observed within a 7-week follow-up. Low-dose prednisolone was the sole remaining medication since lymphodepletion, and it was successfully discontinued without any indications of disease relapse for a period of up to 18 months [ 29 ].

The same team further reported a group of five successful SLE cases with CD19-targeted CAR-T platform [ 23 ]. The patients were between 18 and 24 years old with at least 1 year disease duration, previously treated with pulse glucocorticoids, hydroxychloroquine, mycophenolate, cyclophosphamide and other immunosuppressive drugs. Notably, all five patients received belimumab and one used rituximab. All of them had multiorgan involvement with histology-proven glomerulonephritis, and had active disease at baseline with SLEDAI-2K scores between 8 and 16. The procedures were similar to the first case, but these patients were totally drug free since CAR-T therapy and received a slightly low dose at 1.0 × 10 6 cells/kg body weight. SLEDAI-2K scores, proteinuria, completement C3 levels and anti-dsDNA antibody levels showed a significant improvement within 3 months, as well as patient self-rated fatigue. Circulating B cell numbers fully disappeared from day 2 and remained zero for a prolonged period, while other circulating immune cells recovered within 10 days after treatment. The observed adverse events were limited to Grade 1 CRS in three out of five patients. These Grade 1 CRS cases were effectively managed. All five patients remained drug-free and no SLE flare occurred during follow-up [ 24 ]. In summary, the autologous CD19-targeted CAR-T therapy demonstrated both efficacy and tolerability in active SLE patients, as evidenced by relatively long-term follow-up.

CAR-T therapy has also been reported in severe and refractory SSc [ 25 ]. In one instance, a 60-year-old male with diffuse cutaneous SSc, presenting with anti-RNA polymerase III autoantibodies and multiple organ involvement, underwent CD19-targeted CAR-T therapy at a dosage of 1.0 × 10 6 cells/kg body weight. Due to renal impairment, the patient received a reduced dose of fludarabine and cyclophosphamide for lymphodepletion conditioning. Prior to the therapy, the patient exhibited various disease manifestations, including MRI-confirmed diffuse myocardial fibrosis, high-resolution CT-verified lung fibrosis, right heart catheterization-validated pulmonary hypertension, Raynaud’s phenomenon and carpal arthritis. Despite prior treatment with methotrexate and mycophenolate, the patient experienced treatment failure. Following the CAR-T treatment, there was a noteworthy turnaround in the patient's condition, evidenced by the reversal of anti-RNA polymerase III autoantibodies and significant improvement in heart, lung, joint and skin manifestations at both 3 and 6 months' follow-up. Notably, Grade 1 cytokine-release syndrome was observed, although the administration of tocilizumab was not necessary for management. In comparison with previously reported SLE cases, the patient in this instance was older, further highlighting the remarkable clinical efficacy and tolerability of CD19-targeted CAR-T therapy in the context of severe and refractory systemic sclerosis.

Similar applications have been reported in refractory ASyS, a systemic rheumatic disease manifested as positive anti-synthetase antibody, myositis, interstitial lung disease (ILD), fever, arthritis, mechanic's hands and Raynaud's phenomenon. Two 41-year-old male ASyS patients with anti-Jo-1 antibodies experienced significant improvement and sustained stability following CD19-targeted CAR-T therapy [ 26 , 27 ]. Both patients failed with mutiple immunosuppressants, including rituximab and intravenous immunoglobulins, and presented with severe muscle weakness and progressive shortness of breath at baseline. After CAR-T treatment, both patients showed rapid clinical improvement with negative anti-Jo-1 antibody, decreased creatine kinase level, improved manual muscle test score, and improved Physician Global Assessment score. Although similar, there were differences between these two cases, including the dose of CAR T cells, the dose of glucocorticoids before conditioning, the speed of B cell recovery, and the overall follow-up time. One patient remained drug-free for 180 days, while the other received additional azathioprine (changed to mycophenolate mofetil later) 28 days after CAR T cell infusion. Both patients experienced Grade 1 CRS, and only one patient received tocilizumab.

A further report outlines the course of a 44-year-old lady with ASyS with positive anti-Jo-1, anti-Pm-Scl-100 antibodies and high-level rheumatoid factor [ 28 ]. The patient experienced refractory myositis and arthritis, as well as uncontrolled lung and skin manifestation. She failed on glucocorticoids, cyclophosphamide, mycophenolate, tacrolimus, tofacitinib, tocilizumab, IVIG, rituximab and ocrelizumab, and showed only slight improvement with lenabasum in a clinical trial. Following CD19-targeted CAR-T therapy, a remarkable improvement was noted in muscle, joint and lung conditions, achieving major improvement according to the 2016 ACR/EULAR Total Improvement Score. Moreover, the patient maintained drug-free status during the 150-day follow-up. While experiencing mild CRS, the patient developed mild dizziness 1 week after CAR-T infusion, raising concern for ICANS. Dexamethasone administration promptly resolved the symptoms.

An increasing number of cases are continuing to emerge. In the most recent reports, as of June 2023, the Erlangen (Germany) team has administered CD19-targeted CAR-T therapy to eight patients with treatment-resistant SLE, with the longest follow-up period extending to 24 months [ 30 ], as well as three idiopathic inflammatory myopathy patients and four SSc patients [ 31 ]. Another three patients with severe refractory SLE have been reported recently as a sentinel cohort enrolled in an open-label, single-arm, multicentre phase 1/2 study ( NCT05798117 , Table 3 ) [ 32 ]. Notably, these patients are older compared with SLE patients previously reported, with ages of 58, 48 and 38, respectively. Although the longest follow-up period of these three cases is 106 days, the disclosed data indicate initial efficacy and manageable tolerability.

CAR-T therapy for malignancy comorbid with autoimmune rheumatic diseases

A topic worthy of attention is CAR-T therapy in the treatment of patients with previously diagnosed ARDs who develop haematological malignancies. Patients with autoimmune diseases have an increased risk of developing lymphoproliferative malignancy, especially large B cell, marginal zone and T cell subtypes [ 33 , 34 ]. However, previous clincial trials of CAR-T therapy for B cell lymphoma have excluded patients with history of autoimmune disorders and those on immunosuppressive medications or steroids.

Zhang et al. reported a case in which a lymphoma patient with long-term SLE benefited from CAR-T therapy for both diseases in 2021 [ 35 ]. The 41-year-old female, who was diagnosed with SLE 20 years ago, developed diffuse large B cell lymphoma (DLBCL), and was enrolled in a clinical trial using BCMA/CD19 dual-targeted CAR-T therapy due to side effects of standard R-CHOP chemotherapy. Pretreated with fludarabine and cyclophosphamide and with discontinued maintenance prednisone, she received a single infusion of CAR T cells at a dose of 5.3 × 10 6 /kg body weight. She experienced a remarkable remission of DLBCL, accompanied by negative seroconversion of autoantibodies. The patient had B cell aplasia persisting for 198 days, and maintained a drug-free remission throughout the 23-month follow-up period.

Based on a large-scale electronic health records database in the USA, Wang et al. recently reported on 1363 adult patients diagnosed with B cell non-Hodgkin lymphoma (NHL) and treated with FDA-approved CAR-T therapy from 2019 and 2023 [ 36 ]. Among them, 58 cases (4.3%) had concomitant ARDs, including 24 RA, 13 psoriasis, 10 SLE, five Sjögren's syndrome, four ankylosing spondylitis and two polymyalgia rheumatica. Most patients were on immunosuppressants at baseline, including hydroxychloroquine, methotrexate, mycophenolate and tacrolimus. An additional 58 non-autoimmune patients were selected through propensity score matching, and time to next treatment or death and overall survival showed no significant difference between the two groups. In terms of safety, there was no significant difference regarding CRS, ICANS, or medications for adverse events. Thirteen (31%) patients received prednisone, and five patients restarted hydroxychloroquine and methotrexate within 1 year after CAR-T treatment. Although limited by its retrospective nature, this study provides meaningful evidence for the use of CAR-T therapy in patients with concurrent ARD and B cell NHL [ 37 ].

Advantages over existing immunosuppresive therapies and main concerns

The published ARD cases all involved refractory conditions with significant organ involvement. Prior to undergoing CAR-T therapy, these patients had been treated with various immunosuppressive drugs, but none of them achieved long-term remission or low disease activity. In some instances, B cell-targeted therapies, such as B cell depletion using anti-CD20 monoclonal antibodies and monoclonal antibodies targeting B lymphocyte stimulator (BLyS or BAFF), were used, but they either elicited poor responses or resulted in only transient and partial improvements.

B cell lineages play a key role in autoimmune diseases, including producing pathogenic autoantibodies such as anti-dsDNA antibody in SLE, as well as antibody-independent functions like cytokine secreting leading to tissue inflammation directly, or crosstalk with other immune cells triggering immune intolerance [ 38 , 39 ]. The mechanism of B cells in autoimmune diseases, although not fully elucidated, laid the foundation of B cell depletion therapies [ 40 ]. Belimumab, a fully humanized anti-BLyS monoclonal antibody, is the first approved B cell related biologic for ARDs and is currently approved for use in SLE. With numerous preclinical and clinical evidence, anti-CD20 monoclonal antibody like rituximab has been recommended in many guidelines and widely used in clinical management of SLE [ 41 ], antiphospholipid syndrome [ 42 ], RA [ 43 ], antineutrophil cytoplasmic antibody-associated vasculitis [ 44 ], SSc [ 45 ], IIM [ 46 ] and others, especially in severe cases. However, refractory cases with no or little response to rituximab do exist. A possible reason for variable response to B cell related therapies could be incomplete B cell depletion. Compared with CD20, CD19 is more widely expressed during all phases of B cell development, including pro-B cells and antibody-secreting plasmablasts and plasma cells [ 47 ]. Targeting CD19 is expected to yield a faster, more extensive and profound B cell depletion effect compared with anti-CD20 monoclonal antibody therapy, including long-lived plasma cells residing in the bone marrow, thus further enhancing the therapeutic potential of CD19-targeted approaches [ 40 ].

Drug-free remission was sustained in the follow-up despite the recovery of B cells and immunoglobulins. Notably, in the reported SLE cases, although B cell reconstitution occurred about 100 days after CAR-T infusion, immune phenotyping and B cell receptor sequencing indicated these B cells had a naïve phenotype [ 23 ], suggesting that the B cell compartment had been reset successfully [ 48 ]. On the other hand, recovered immunoglobulin levels suggested that compared with traditional regimens such as pulse glucocorticoids, CAR-T therapy would not bring comprehensive immunosuppression despite the pre-treatment lymphocyte depletion. Although the experience in cancers shows that disease relapses may occur following CAR T cell infusion, the observed drug-free remission in selected case reports has thus far exceeded expectations. Persistent serological conversion to negative has been reported in SLE cases in follow-up after CAR T therapy, while vaccine-related immune responses are preserved [ 30 ]. If remission or low disease activity can be maintained for a longer period, the drug burden of patients will be greatly reduced, including the long-term side effects of glucocorticoids.

Due to the limited extent of preclinical research and clinical reports, several concerns persist regarding the implementation of CAR-T therapy. Two major adverse events, CRS and ICANS, commonly observed in haematological malignancies [ 26 ], have also been reported in ARDs. The diverse organ involvements in ARD patients may pose challenges in managing adverse events. For example, fever, a common symptom of CRS, may complicate the management of patients with ILD [ 31 ]. Additionally, other considerations involve the waiting time required for in vitro engineering and the efficacy of bridging therapies. Disease deterioration has been observed during immunosuppressant washout prior to lymphodepletion therapy [ 32 ]. The risk of life-threatening infections due to lymphodepletion pre-processing further adds to safety concerns [ 27 , 28 ].

B cells might only represent a partial aspect of these diseases, rather than encompassing the entirety of their pathogenesis. The ASyS case mentioned earlier [ 13 ] exemplifies this complexity, wherein enhanced CD8 + T cells were detected in circulation following CAR-T treatment, leading to the incorporation of additional T cell suppressive drugs due to concerns about potential relapse. A recent report of the failure of murine CD19-targeted CAR-T therapy on an SSc animal model also suggested that CAR-T design should be consistent with disease pathogenesis [ 49 ]. The study used a Fra-2 transgenic mouse model, which could well mimic the fibrosis and vasculopathy of SSc but lacks the typical autoimmune response [ 50 , 51 ]. Although CD19-targeted CAR-T combined with anti-CD20 monoclonal antibody achieved deeper B cell depletion in the peripheral blood and lungs of Fra-2 mice than anti-CD20 monoclonal antibody alone, it did not improve overall outcomes, and even worsened the pulmonary fibrosis and pulmonary hypertension [ 49 ]. This is partly because B cells do not play a key role in the pathogenesis of Fra-2 transgenic mice, verified by the result that the anti-CD20 monoclonal antibody group did not show a significant difference compared with the control group. Meanwhile, lack of lymphodepletion pre-processing may lead to the activation of T cells. The report once again confirms the importance of CAR-T design and treatment subject selection.

To fully comprehend the safety and efficacy of this novel therapy, longer follow-up observations and randomized controlled trials are imperative. Moreover, the high cost currently restricts widespread application, particularly considering the potential necessity for repeated treatments. The durability and tolerability of repeated CAR-T therapy in ARDs remain unclear.

Potentials of CAR-based therapy and ongoing clinical trials

Although the CAR T cells used in the reported ARD cases without malignancy were all CD19-targeted cells generated by lentiviral transduction into autologous T cells, CAR therapy has more diverse designs. We summarize the ongoing CAR-based clinical trials in ARDs in Table 3 , and many variant products based on the CAR prototype have been registered for clinical research. Notably, although we focus on rheumatic diseases, the application of CAR-based therapy in other autoimmune diseases has made impressive progress.

The diversity of antigen-binding domains could broaden the targeting field of CAR [ 52 ]. In addition to CD19, BCMA, which is almost exclusively expressed on plasmablasts and plasma cells and regulates B cell proliferation, maturation and survival, is a popular target. As mentioned above, BCMA-targeted CAR-T therapy has been approved for the treatment of refractory multiple myeloma, and phase 1 trial interim results of anti-BCMA CAR-T therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders have been published [ 53 ]. Several clinical trials using BCMA-targeted CAR-T therapy or even BCMA/CD19 dual-targeted CAR-T therapy are planned in refractory ARDs, including SLE, Sjögren's syndrome, immune-mediated necrotizing myopathies, scleroderma and vasculitis ( Table 3 ). Another potential target is CD7, a transmembrane glycoprotein expressed by T cells and NK cells and their precursors. Theoretically, targeting CD7 is more effective than CD19 for autoimmune diseases with abnormal activation of T cells. Anti-CD7 CAR-T therapy has been reported effective in treating T cell malignancies, and a clinical trial in refractory dermatomyositis, Still’s disease and inflammatory bowel diseases is recruiting ( NCT05239702 ). Besides, the extracellular antigen-binding domain of CAR is usually a scFv but can also be designed as antibody-receptors or ligands. Chimeric autoantibody receptor T cells (CAART) provides a more exquisite targeting to cells expressing specific antibodies, which may be more effective in autoimmune diseases caused by pathogenic autoantibodies. CAART has been used in autoimmune neurological and dermatological diseases, targeting anti-muscle specific tyrosine kinase (MuSK) and anti-desmoglein 3 (DSG3) autoantibodies, and related clinical trials are ongoing in anti-MuSK antibody positive myasthenia gravis and anti-DSG3 antibody positive mucosal-dominant pemphigus vulgaris ( NCT05451212 , NCT04422912 ).

New generations of CAR are characterized by a combination of co-stimulatory domains or additional domains activating different intracellular signalling pathways, which aims to strengthen and prolong the expected effect of CAR T cells in vivo . One trial registered ( NCT05459870 ) claimed to apply 4SCAR T cells, which is the fourth generation supposed to combine three co-stimulatory motifs as the intracellular domain. Similar products based on 4SCAR-T from the same institute have been reported safe and well tolerated in glioblastoma and paediatric neuroblastoma [ 54 , 55 ].

Other cutting-edge updates are emerging to engineer safer and more effective CAR immune cells [ 56 , 57 ]. Other than virus transduction, gene editing, especially mRNA technology, is another way to synthesize CAR T cells [ 58 ]. T cell-targeted lipid nanoparticles delivering modified mRNA was previously reported to treat cardiac injury in vivo [ 59 ]. Recently, Granit et al. [ 60 ] reported the phase 1b/2a result of a prospective, multicentre, open-label, non-randomized study that uses RNA-engineered BCMA-targeted CAR T cells in myasthenia gravis. Unlike conventional DNA-engineered CAR T cells, RNA-engineered CAR T cells do not persist long term and do not require lymphodepletion. The treatment was well tolerated with no adverse events typically associated with DNA-based CAR T cells (such as CRS) reported.

Gene editing technique also makes allogeneic CAR-T therapy possible [ 61 ] ( Fig. 2 ). Allogeneic T cells could shorten the waiting time for infusion and reduce the cost of treatment, but it may cause life-threatening graft- vs -host disease (GVHD), and may be rejected by host immune systems [ 62 ]. Gene editing eliminates TCR expression and makes allogeneic CAR T cells undetectable by the host immune system, and thus could control the risk of GVHD. Except gene editing, choosing an appropriate cell source can also reduce the occurrence of GVHD. Although there are still challenges to be resolved in allogeneic CAR therapy, some products generated by universal platforms have entered clinical trial, including in ARDs ( NCT05859997 ). Besides, CARs can be synthesized not only on the surface of T cells, but also on NK cells [ 63 , 64 ], Tregs [ 65 ] or even macrophages ( Fig. 2 ) [ 66 ]. CARs based on different cells can have different functional characteristics.

Although reported applications in ARDs are all in adult patient, CAR therapy has proven well tolerated in children [ 67 ]. Due to the chronic relapsing nature of ARDs, paediatric patients usually have higher cumulative exposure to glucocorticoids and other immunosuppressants than adults. It is encouraging to note that numerous ongoing clinical studies have included paediatric patients ( Table 3 ).

Conclusion

In conclusion, CD19-targeted CAR-T therapy is rapidly emerging as a potential treatment option for autoimmune rheumatic diseases. The success of future clinical trials hinges on designing CAR-based immune cells tailored according to the pathogenesis of various ARDs. Utilizing appropriate CAR engineering technology to minimize toxicity and maximize therapeutic efficacy is of paramount importance. Equally critical is the judicious selection of suitable subject populations for trials.

We maintain an optimistic yet cautious outlook on the application of CAR immune cell therapy in ARDs, and planned clinical trials will shed further light on efficacy and safety, thereby consolidating its potential as a promising future therapeutic strategy for ARDs.

Contributor Information

Xia Lyu, Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Epidemiology and Public Health Group, School of Health Sciences, The University of Manchester, Manchester, UK; Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

Latika Gupta, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK; Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK.

Eleni Tholouli, Department of Haematology, Manchester Royal Infirmary, Manchester, UK.

Hector Chinoy, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK; Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK.

Data availability

The data underlying this article are available in the article.

Funding

H.C. is supported by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (Grant number: NIHR203308). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. X.L. is supported by the China Scholarship Council (CSC) (Grant number: 202206230007).

Disclosure statement : H.C. has received consulting fees as a speaker for GSK and UCB; is an Advisory Board member for Astra Zeneca, Pfizer, Argenx and Galapagos; is Data and Science Monitoring Board chair for Horizon Therapeutics; and is UK Chief Investigator for a planned CAR-T study with Cabaletta Bio. E.T. has received consulting fees as a speaker for Astellas, Jazz, Kite/Gilead, Novartis, Pfizer and Vertex; is an Advisory Board member for Autolus, BMS/Celgene, Janssen, Jazz, Kite/Gilead, Novartis and Vertex; and is a developer of educational materials for Jazz.

References

1. Lee DW, Santomasso BD, Locke FL. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625–38.

2. Gross G, Waks T, Eshhar Z.. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci 1989;86:10024–8.

3. Eshhar Z, Waks T, Gross G, Schindler DG.. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci 1993;90:720–4.

4. Neelapu SS, Locke FL, Bartlett NL. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531–44.

5. Schuster SJ, Bishop MR, Tam CS. et al. ; JULIET Investigators . Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019;380:45–56.

6. Labanieh L, Mackall CL.. CAR immune cells: design principles, resistance and the next generation. Nature 2023;614:635–48.

7. Kanate AS, Majhail N, DeFilipp Z. et al. Updated indications for immune effector cell therapy: 2023 guidelines from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther 2023;29:594–7.

8. Hayden PJ, Roddie C, Bader P. et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 2022;33:259–75.

9. Yakoub-Agha I, Chabannon C, Bader P. et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 2020;105:297–316.

10. Santomasso BD, Nastoupil LJ, Adkins S. et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol 2021;39:3978–92.

11. Kuhnl A, Roddie C, Kirkwood AA. et al. A national service for delivering CD19 CAR-Tin large B-cell lymphoma—The UK real-world experience. Br J Haematol 2022;198:492–502.

12. Locke FL, Ghobadi A, Jacobson CA. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019;20:31–42.

13. Oluwole OO, Bouabdallah K, Munoz J. et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol 2021;194:690–700.

14. Jacobson CA, Chavez JC, Sehgal AR. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23:91–103.

15. Locke FL, Miklos DB, Jacobson CA. et al. ; All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 2022;386:640–54.

16. Jacobson CA, Munoz J, Sun F. et al. Real-world outcomes with CAR T-cell therapies in large B-cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther 2023.

17. Wang M, Munoz J, Goy A. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382:1331–42.

18. Wang M, Munoz J, Goy A. et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol 2023;41:555–67.

19. Shah BD, Ghobadi A, Oluwole OO. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 2021;398:491–502.

20. Baker DJ, Arany Z, Baur JA, Epstein JA, June CH.. CAR T therapy beyond cancer: the evolution of a living drug. Nature 2023;619:707–15.

21. Kansal R, Richardson N, Neeli I. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 2019;11. 10.1126/scitranslmed.aav1648.

22. Mougiakakos D, Krönke G, Völkl S. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 2021;385:567–9.

23. Mackensen A, Muller F, Mougiakakos D. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022;28:2124–32.

24. Taubmann J, Müller F, Boeltz S. et al. OP0141 long term safety and efficacy of car-T cell treatment in refractory systemic lupus erythematosus—data from the first seven patients. Ann Rheum Dis 2023;82(Suppl 1):93–4.

25. Bergmann C, Muller F, Distler JHW. et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis 2023;82:1117–20.

26. Muller F, Boeltz S, Knitza J. et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 2023;401:815–8.

27. Pecher AC, Hensen L, Klein R. et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 2023;329:2154–62.

28. Taubmann J, Knitza J, Müller F. et al. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T-cells after failure of several B cell depleting antibodies. Rheumatology 2023. 10.1093/rheumatology/kead330.

29. Schett G, Mackensen A, Mougiakakos D.. CAR T-cell therapy in autoimmune diseases. Lancet 2023.

30. Schett GM, Taubmann J, Aigner M. et al. CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained[abstract]. Arthritis Rheumatol 2023;75(Suppl 9). https://acrabstracts.org/abstract/car-t-cell-therapy-leads-to-long-term-abrogation-of-autoimmunity-in-sle-patients-while-vaccination-responses-are-maintained/ .

31. Taubmann JM, Aigner M, Minopoulou I. et al. Tolerability of CAR T Cell Therapy in Autoimmune Disease [abstract]. Arthritis Rheumatol 2023;75(Suppl 9). https://acrabstracts.org/abstract/tolerability-of-car-t-cell-therapy-in-autoimmune-disease/ .

32. Hernández C, BP J, Linares Alberich M. et al. An open-label, multicenter, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323, a rapid manufacturing CAR-T cell therapy targeting CD19 on B cells, for severe refractory systemic lupus erythematosus: preliminary results [abstract]. Arthritis Rheumatol 2023;75(Suppl 9). https://acrabstracts.org/abstract/an-open-label-multicenter-phase-1-2-study-to-assess-safety-efficacy-and-cellular-kinetics-of-ytb323-a-rapid-manufacturing-car-t-cell-therapy-targeting-cd19-on-b-cells-for-severe-refractory-system/ .

33. Anderson LA, Gadalla S, Morton LM. et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009;125:398–405.

34. Ekstrom Smedby K, Vajdic CM, Falster M. et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029–38.

35. Zhang W, Feng J, Cinquina A. et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR. Stem Cell Rev Rep 2021;17:2120–3.

36. Wang J, Alkrekshi A, Dasari S. et al. CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study. Bone Marrow Transplant 2023;58:1223–8.

37. Bachanova V, Nachman PH.. Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders. Bone Marrow Transplant 2023;58:1175–6.

38. Shen P, Fillatreau S.. Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol 2015;15:441–51.

39. Rawlings DJ, Metzler G, Wray-Dutra M, Jackson SW.. Altered B cell signalling in autoimmunity. Nat Rev Immunol 2017;17:421–36.

40. Lee DSW, Rojas OL, Gommerman JL.. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov 2021;20:179–99.

41. Fanouriakis A, Kostopoulou M, Alunno A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736–45.

42. Cohen H, Cuadrado MJ, Erkan D. et al. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Lupus 2020;29:1571–93.

43. Smolen JS, Landewe RBM, Bergstra SA. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82:3–18.

44. Hellmich B, Sanchez-Alamo B, Schirmer JH. et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 2023. 10.1136/ard-2022-223764.

45. Pope JE, Denton CP, Johnson SR. et al. State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol 2023;19:212–26.

46. Oldroyd AGS, Lilleker JB, Amin T. et al. ; British Society for Rheumatology Standards, Audit and Guidelines Working Group. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) 2022;61:1760–8.

47. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM.. The generation of antibody-secreting plasma cells. Nat Rev Immunol 2015;15:160–71.

48. Duarte JH. CAR-T cells tackle autoimmunity. Nat Biotechnol 2022;40:1575.

49. Avouac J, Cauvet A, Orvain C. et al. Effects of B cell depletion by CD19-targeted CAR-T cells in a murine model of systemic sclerosis. Arthritis Rheumatol 2023;

50. Maurer B, Reich N, Juengel A. et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012;71:1382–7.

51. Asano Y, Sato S.. Animal models of scleroderma: current state and recent development. Curr Rheumatol Rep 2013;15:382.

52. Finkel TH, Radic M.. Chimeric receptors broaden the therapeutic landscape for autoimmune disease. Nat Rev Rheumatol 2023;19:327–8.

53. Qin C, Tian DS, Zhou LQ. et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther 2023;8:5.

54. Liu Z, Zhou J, Yang X. et al. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. Mol Cancer 2023;22:3.

55. Yu L, Huang L, Lin D. et al. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients. J Cancer Res Clin Oncol 2022;148:2643–52.

56. Rafiq S, Hackett CS, Brentjens RJ.. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 2020;17:147–67.

57. Liu Y, Sperling AS, Smith EL, Mooney DJ.. Optimizing the manufacturing and antitumour response of CAR T therapy. Nat Rev Bioeng 2023;1:271–85.

58. Wu J, Wu W, Zhou B, Li B.. Chimeric antigen receptor therapy meets mRNA technology. Trends Biotechnol 2023. 10.1016/j.tibtech.2023.08.005.

59. Rurik JG, Tombacz I, Yadegari A. et al. CAR T cells produced in vivo to treat cardiac injury. Science 2022;375:91–6.

60. Granit V, Benatar M, Kurtoglu M. et al. ; MG-001 Study Team. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol 2023;22:578–90.

61. Cooper LJN, Al-Kadhimi Z, DiGiusto D. et al. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis 2004;33:83–9.

62. Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L.. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 2020;19:185–99.

63. Ruppel KE, Fricke S, Kohl U, Schmiedel D.. Taking lessons from CAR-T cells and going beyond: tailoring design and signaling for CAR-NK cells in cancer therapy. Front Immunol 2022;13:822298.

64. Laskowski TJ, Biederstadt A, Rezvani K.. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer 2022;22:557–75.

65. Stucchi A, Maspes F, Montee-Rodrigues E, Fousteri G.. Engineered Treg cells: the heir to the throne of immunotherapy. J Autoimmun 2023;102986.

66. Pan K, Farrukh H, Chittepu V. et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res 2022;41:119.

67. PDQPTE Board. Pediatric Chimeric Antigen Receptor (CAR) T-Cell Therapy (PDQ ® ): health Professional Version. PDQ cancer information summaries. Bethesda, MD: National Cancer Institute (US; ), 2002.

Associated Data

Data Availability Statement

The data underlying this article are available in the article.